Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Strategic Priorities and Business Outlook
BMY logo

BMY Growth Portfolio Surges 17% to $6.8B Amid Legacy Declines

BMY10-QFiling Date: 10/30/2025
Bristol Myers Squibb Company
Description

What this story covers

Bristol Myers Squibb's Q3 2025 10-Q shows $12B revenues up 3%, driven by 17% growth in oncology and cardio portfolio to $6.8B, offsetting 13% legacy drop from generics. Productivity savings target $2B by 2027; pipeline bolstered by $1.5B BioNTech deal. Net debt falls to $32.1B with $12.2B ops cash. Risks from IRA pricing persist, but innovation positions for resilience.

Story snapshot

CompanyBristol Myers Squibb Company
TickerBMY
VariantStandard detailed
Duration14:59
Filing type10-Q
PeriodQ3 2025
IndustryHealthcare & Pharmaceuticals
Accession0000014272-25-000149

Full Story Script

Content not available for this story.

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in